<DOC>
	<DOCNO>NCT01096095</DOCNO>
	<brief_summary>DESIGN : Pilot , Phase II , double-blind , placebo-controlled study JUSTIFICATION : In literature one find pharmacological treatment change natural history Spinocerebellar ataxtia type 3 ( SCA3 ) . Patients disease invariably become dependent . OBJECTIVES I . To determine safety tolerability phenylbutyrate patient SCA3 . II . To provide early subsidy efficacy phenylbutyrate SCA3 . DURATION : 12 month double-blind study . PLACE OF REALIZATION : Hospital de Cl√≠nicas de Porto Alegre , Brazil . NUMBER OF PATIENTS : 20 patient . CONCOMITANT MEDICATIONS : There concomitant medication prohibit unless affect safety parameter study ( hemogram platelet ; fast serum glucose , AST , ALT , Gamma-GT , Bilirubins , Prothrombin time , Creatinine , Urea , Na , K , chlorides arterial gasometry ; electrocardiogram echocardiogram ) . MEDICATIONS UNDER INVESTIGATION : Powdered sodium phenylbutyrate sachet contain 3g . At start study , dose 15g/day ( five sachet ) may reduce case mild adverse event . OUTCOMES Primary safety outcome : The number adverse event , interruption dose reduction two group ( case control ) . Efficacy outcome : Efficacy outcomes follow score group : NESSCA , SARA , Barthel , BDI , WHOQol .</brief_summary>
	<brief_title>Pilot Study Safety Efficacy Sodium Phenylbutyrate Spinocerebellar Ataxia Type 3</brief_title>
	<detailed_description />
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Spinocerebellar Ataxias</mesh_term>
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<mesh_term>Machado-Joseph Disease</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<criteria>1 . All patient shall molecular diagnosis confirm expanded polyglutamine tract ( CAG ) measure already determine . 2 . Patients still able walk 8 year disease duration , 3 . Patients age 16 year invite participate study . 1. show electrocardiogram ou echocardiographic alteration suggestive heart insufficiency baseline ; 2. serum creatinine level higher 1.2 mg/dL , confirmation renal insufficiency due rate glomerular filtration ; 3. show history hypersensibility sodium phenylbutyrate , 4. ( men woman ) agree use reliable contraceptive method entire study period three month end .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>SCA</keyword>
	<keyword>Spinocerebellar Ataxia</keyword>
	<keyword>Sodium Phenylbutyrate</keyword>
	<keyword>Machado-Joseph Disease</keyword>
	<keyword>Treatment</keyword>
</DOC>